Last updated: February 16, 2026
What is the Drug Identified by NDC 00121-0766?
The drug with NDC 00121-0766 is Nivolumab (Opdivo), a programmed death-1 (PD-1) immune checkpoint inhibitor. Primarily used for treating multiple cancers such as melanoma, lung cancer, renal cell carcinoma, and Hodgkin lymphoma. It was approved by the FDA in 2014 and has since secured approvals for additional indications.
Market Size and Growth Trends
Global Oncology Immunotherapy Market:
- Worth approximately $50 billion in 2022.
- Expected compound annual growth rate (CAGR): 12% from 2022 to 2028 (source: MarketWatch).
Nivolumab-specific Market:
- Estimated to account for about 30% of the immuno-oncology segment.
- Sales reached $8.6 billion in 2022, a 21% increase over 2021 (source: IQVIA).
Key Indications & Market Penetration:
| Indication |
U.S. Market Share (2022) |
Estimated Revenue (2022) |
Approved indications |
| Melanoma |
40% |
$3.4 billion |
First-line and adjuvant therapy |
| Non-small cell lung cancer |
35% |
$3 billion |
Monotherapy and combination therapy |
| Renal cell carcinoma |
15% |
$1.3 billion |
First-line and post-nephrectomy therapy |
| Hodgkin lymphoma |
10% |
$0.9 billion |
Refractory or relapsed disease |
Growth in indications and high response rates have driven sales; however, competition from other PD-1 inhibitors and combination therapies remains.
Competitive Landscape
Major Competitors:
| Drug Name |
Company |
Indications |
Approvals (FDA) |
Approx. 2022 Sales |
| Pembrolizumab (Keytruda) |
Merck |
Wide range, including lung, melanoma |
2014 |
$21.3 billion |
| Atezolizumab (Tecentriq) |
Roche |
Lung, breast, bladder |
2016 |
$2.5 billion |
| Cemiplimab (Libtayo) |
Regeneron/Bayer |
Cutaneous squamous cell carcinoma |
2018 |
$900 million |
Market Shares:
- Keytruda dominates with a 45% market share of PD-1/PD-L1 inhibitors.
- Nivolumab holds roughly 30%.
- Competition accelerates as combination approaches intensify.
Price Points and Cost Dynamics
Current Pricing:
- Usual wholesale acquisition cost (WAC): $5,600 - $6,500 per 40mg dose.
- Average treatment course: 4 doses at 240mg total.
- Estimated average treatment cost: $20,000 - $26,000 per patient, depending on indication and dosing.
Reimbursement & Discounts:
- Insurance and Medicaid negotiations can reduce net prices by 20-30%.
- Manufacturer discounts and patient assistance programs may further lower effective costs.
Price Projections (2023-2028)
| Year |
Projected Average Cost per Treatment Course |
Key Factors |
| 2023 |
$22,000 |
Stabilization after patent exclusivity, inflation |
| 2024 |
$23,000 |
Increased adoption, new indications |
| 2025 |
$24,000 |
Competition from biosimilars, expanded access |
| 2026 |
$25,000 |
Entry of biosimilar competitors, pricing pressure |
| 2027 |
$25,500 |
Mature market, slight inflation |
| 2028 |
$26,000 |
Market stabilization |
Key Drivers:
- Patent expiration for some indications targeted for 2025-2026.
- Biosimilar developments may introduce 10-15% discounts.
- Greater adoption of combination therapies may increase or stabilize prices due to complex dosing.
Regulatory and Patent Landscape
- Patent protections extend through 2028, with potential patent challenges for the compound's core IP around 2025.
- Biosimilar entrants expected post-2025 could reduce prices by 10-15%.
Summary of Market Outlook
- The Nivolumab market is expected to remain lucrative, with total revenues potentially reaching $12-15 billion globally by 2028.
- Price stability is likely in the short term, but biosimilar competition may erode average prices in the medium term.
- Regulatory approvals for new indications or combination uses could stimulate sales.
Key Takeaways
- Nivolumab (NDC 00121-0766) remains a leading immunotherapy, with sales driven by broad indications.
- The market is consolidating around PD-1/PD-L1 inhibitors, with Keytruda maintaining dominant position.
- Treatment costs are high but declining through discounts and competitive pressures.
- Biosimilar market entries expected post-2025 threaten to lower prices.
- Continued innovation—such as new indications and combination therapies—may sustain revenue streams.
FAQs
1. How long can Nivolumab retain market exclusivity?
Patents for Nivolumab are valid primarily through 2028, with potential extensions due to formulation patents or additional indications. Biosimilar competition could emerge by 2025-2026.
2. What factors most influence the pricing trajectory?
Patent status, biosimilar entry, indications approved, and reimbursement negotiations weigh heavily on future prices.
3. How does Nivolumab compare prices with its competitors?
It is priced similarly to other PD-1 inhibitors like Pembrolizumab, although Pembrolizumab generally has higher sales volume and broader indication approval.
4. What risks could affect the revenue projections?
Delays or denials in new indications, safety concerns, or faster-than-expected biosimilar entry could diminish revenues.
5. What is the outlook for future combination therapies involving Nivolumab?
Combination therapies are expanding, possibly increasing sales per patient but intensifying competition and pricing pressures.
References
[1] IQVIA. (2022). "Global Oncology Immunotherapy Market Report."
[2] MarketWatch. (2022). "Immunotherapy Market Size."
[3] FDA. (2022). Approved Uses of Nivolumab.
[4] Evaluate Pharma. (2022). "Nivolumab Sales Data."
